O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma

International Journal of Clinical Oncology

Volumn 15, Issue 4, 2010, Pages 352-358

  Sonoda, Yukihiko ^a   Yokosawa, Michiko ^a   Saito, Ryuta ^a   Kanamori, Masayuki ^a   Yamashita, Yoji ^a   Kumabe, Toshihiro ^a   Watanabe, Mika ^b   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Glioblastoma; Immunohistochemistry; Methylation specific polymerase chain reaction; O6 Methylguanine DNA methyltransferase

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DNA ISOLATION; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 77955716591     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0065-6     Document Type: Article

References (38)

1. Roth JG, Elvidge AR (1960) Glioblastoma multiforme: A clinical survey. J Neurosurg 17:736-750
2. Salford LG, Brun A, Nirfalk S (1988) Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 69:506-509
3. Chandler KL, Prados MD, Malec M et al (1993) Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32:716-720
4. Devaux BC, O'Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767-775
5. Salvati M, Cervoni L, Artico M et al (1998) Long-term survival in patients with supratentorial glioblastoma. J Neurooncol 36:61-64
6. Scott JN, Rewcastle NB, Brasher PM et al (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46:183-188
7. Shinojima N, Kochi M, Hamada J et al (2004) The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101:219-226
8. Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596-2606
9. Kamiryo T, Tada K, Shiraishi S et al (2004) Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treatedwith surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2- chloroethyl)- 3-nitrosourea-based chemotherapy. Neurosurgery 54:349-357
10. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
11. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
12. Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797
13. Watts GS, Pieper RO, Costello JF et al (1997) Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612-5619
14. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
15. Anda T, Shabani HK, Tsunoda K et al (2003) Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysis. Neurol Res 25:241-248
16. Sonoda Y, Kumabe T, Watanabe M et al (2009) Long-term survivors of glioblastoma: Clinical features and molecular analysis. Acta Neurochir (Wien) 151:1349-1358
17. Nakasu S, Fukami T, Baba K et al (2004) Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the nonneoplastic and neoplastic components of gliomas. J Neurooncol 70:333-340
18. Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167-5174
19. Chinot OL, Barrié M, Fuentes S et al (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25:1470-1475
20. Crinière E, Kaloshi G, Laigle-Donadey F et al (2007) MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83:173-179
21. Capper D, Mittelbronn M, Meyermann R et al (2008) Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: Proposal of a feasible immunohistochemical approach. Acta Neuropathol 115:249-259
22. Nakagawa T, Ido K, Sakuma T et al (2009) Prognostic significance of the immunohistochemical expression of O(6)-methylguanine- DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 29:379-388
23. Lee SM, Reid H, Elder RH et al (1996) Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: Possible significance in nitrosourea therapy. Carcinogenesis 17:637-641
24. Grasbon-Frodl EM, Kreth FW, Ruiter M et al (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121:2458-2464
25. Jeuken JW, Cornelissen SJ, Vriezen M et al (2007) MS-MLPA: An attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87:1055-1065
26. Preusser M, Charles Janzer R et al (2008) Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: Observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532
27. Rodriguez FJ, Thibodeau SN, Jenkins RB et al (2008) MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16:59-65
28. Mellai M, Caldera V, Annovazzi L et al (2009) MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics 6:219-227
29. Balaña C, Ramirez JL, Taron M et al (2003) O6-Methylguanine- DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9:1461-1468
30. Blanc JL, Wager M, Guilhot J et al (2004) Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68:275-283
31. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874
32. Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933-4938
33. Watanabe T, Katayama Y, Komine C et al (2005) O6-methylguanine- DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113:581-587
34. Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199
35. Cao VT, Jung TY, Jung S et al (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866-875
36. Friedman HS, McLendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857
37. Andersson U, Malmer B, Bergenheim AT et al (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21-27
38. Nagane M, Kobayashi K, Ohnishi A et al (2007) Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 37:897-906